EQS-News : PolyPeptide Group lanciert Börsengang -2-

PolyPeptide Group Michael Stäheli, Head of Investor Relations & Corporate Communications [e-mail] [phone]

Lemongrass Communications [e-mail], [e-mail] [phone]

Über PolyPeptide Group

PolyPeptide ist ein Auftragsentwickler und -Hersteller (CDMO) im Bereich proprietärer und generischer Peptide in GMP-Qualität, die von Pharma- und Biotech-Unternehmen in zugelassenen pharmazeutischen Produkten, Medikamenten in der klinischen Entwicklung sowie in Generika eingesetzt werden. Das Unternehmen, dessen Anfänge ins Jahr 1952 zurückreichen, stellt heute rund die Hälfte aller derzeit zugelassenen Peptidwirkstoffe her und verfügt über eine globale Präsenz mit sechs GMP-zertifizierten Produktionsanlagen in Europa, den USA und Indien. Als multinationales Unternehmen mit über 900 Mitarbeitenden vereint PolyPeptide umfassendes Wissen und Erfahrung. PolyPeptide ist organisch und durch selektive Akquisitionen bestehender Expertise gewachsen und ist heute ein führendes Unternehmen in der ausgelagerten Peptidherstellung. Weitere Informationen finden Sie unter polypeptide.com.

PolyPeptide Group AG, Dammstrasse 19, 6300 Zug, Schweiz

Disclaimer

This document is not an offer to sell or a solicitation of offers to purchase or subscribe for shares. This document is not a prospectus within the meaning of the Swiss Financial Services Act and not a prospectus under any other applicable laws. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.

A decision to invest in securities of PolyPeptide Group should be based exclusively on the offering prospectus published by PolyPeptide Group AG (the "Company") for such purpose. Copies of the offering prospectus and any other supplements to the offering prospectus are/will be available free of charge in Switzerland for 12 months following the first day of trading on SIX Swiss Exchange at Credit Suisse AG, Zurich, Switzerland (email: [e-mail]). In addition, copies of the offering prospectus and any other supplements to the offering prospectus are/will be available free of charge in Switzerland from PolyPeptide Group AG, Investor Relations, Dammstrasse 19, 6300 Zug, Switzerland (phone: [phone]; email: [e-mail]).

This document is not for publication or distribution in the United States of America (including its territories and possessions, any State of the United States and the District of Columbia), Canada, Japan or Australia or any other jurisdiction into which the same would be unlawful. This document does not constitute an offer or invitation to subscribe for or purchase any securities in such countries or in any other jurisdiction into which the same would be unlawful. In particular, the document and the information contained herein should not be distributed or otherwise transmitted into the United States of America or to publications with a general circulation in the United States of America. The securities referred to herein (the "Securities") have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or the laws of any state, and may not be offered or sold in the United States of America absent registration under or an exemption from registration under the Securities Act. There will be no public offering of the Securities in the United States of America.

This document does not constitute an "offer of securities to the public" within the meaning of Regulation (EU) 2017/ 1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the "UK Prospectus Regulation") of the Securities in the United Kingdom (the "UK"). Any offers of the Securities in the UK will be made pursuant to an exemption under the UK Prospectus Regulation from the requirement to produce a prospectus for offers of the Securities. In the UK, this document is only addressed to qualified investors within the meaning of the UK Prospectus Regulation. In addition, this document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FSMA Order") or (iii) persons falling within Articles 49(2)(a) to (d), "high net worth companies, unincorporated associations, etc." of the FSMA Order, and (iv) persons to whom an invitation or inducement to engage in investment activity within the meaning of Section 21 of the Financial Services and Markets Act 2000 may otherwise be lawfully communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). The Securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

This document does not constitute an "offer of securities to the public" within the meaning of Regulation (EU) 2017/ 1129 of the European Union, as amended (the "Prospectus Regulation") in any member state of the European Economic Area (the "EEA"). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Regulation from the requirement to produce a prospectus for offers of the Securities. In any member state of the EEA, this document is only addressed to qualified investors in that relevant member state within the meaning of the Prospectus Regulation.

Identification of Target Market

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Securities have been subject to a product approval process by each underwriter (as defined below) established in the EEA, which has determined that the Securities are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "MiFID II Target Market Assessment").

Solely for the purposes of the product governance requirements of Chapter 3 of the FCA Handbook Product Intervention and Product Governance Sourcebook (the "UK Product Governance Requirements"), and /or any equivalent requirements elsewhere, and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the UK Product Governance Requirements and/or any equivalent requirements elsewhere) may otherwise have with respect thereto, the Securities have been subject to a product approval process by each underwriter (as defined below) established in the UK, which has determined that the Securities are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in Chapter 3 of the FCA Handbook Conduct of Business Sourcebook; and (ii) eligible for distribution through all permitted distribution channels (the "UK Target Market Assessment").

Notwithstanding the MiFID II Target Market Assessment and the UK Target Market Assessment, distributors should note that: the price of the Securities may decline and investors could lose all or part of their investment; the Securities offer no guaranteed income and no capital protection; and an investment in the Securities is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom.

The MiFID II Target Market Assessment and the UK Target Market Assessment are without prejudice to any contractual, legal or regulatory selling restrictions in relation to the offering of the Securities.

Furthermore, it is noted that, notwithstanding the MiFID II Target Market Assessment, the underwriters (as defined below) established in the EEA will only procure investors who meet the criteria of professional clients and eligible counterparties under MiFID II and that, notwithstanding the UK Target Market Assessment, the underwriters established in the UK will only procure investors who meet the criteria of professional clients and eligible counterparties under Chapter 3 of the FCA Handbook Conduct of Business Sourcebook. For the avoidance of doubt, the MiFID II Target Market Assessment and the UK Target Market Assessment do not constitute: (a) in the case of the MiFID II Target Market Assessment, an assessment of suitability or appropriateness for the purposes of MiFID II and in the case of the UK Target Market Assessment, an assessment of suitability or appropriateness for the purposes of Chapters 9A or 10A respectively of the FCA Handbook Conduct of Business Sourcebook; or (b) a recommendation to any investor or

(MORE TO FOLLOW) Dow Jones Newswires

April 21, 2021 01:01 ET (05:01 GMT)